Antibody-drug conjugates (ADCs) targeting the RON receptor, a tumorigenic factor contributing to cancer malignancy, has been considered as a novel strategy for cancer therapy. Here the authors describe a humanized antibody recognizing the RON plexin-semaphorin-integrin (PSI) domain with increased drug delivery capability for potential clinical application. They conclude that H5B14-based ADCs targeting the RON PSI domain are superior in inducing RON internalization, leading to robust drug delivery and overall inhibition and eradication of tumors in multiple xenograft models.Authors: Xiang-Min Tong, Liang Feng, Sreedhar Reddy Suthe, Tian-Hao Weng, Chen-Yu Hu, Yi-Zhi Liu, Zhi-Gang Wu, Ming-Hai Wang and Hang-Ping YaoPublished as a research article in the Journal for ImmunoTherapy of Cancer (2019) 7:250.#ExperimentalSystems#MonoclonalAntibodies#AntibodyDrugConjugates#JournalArticle#JournalforImmunoTherapyofCancer#Researcher#2019
This library resource entry requires a SITC CONNECT account. Click the Sign In button at the top of this page, otherwise click here to create a FREE SITC CONNECT.
With a free SITC CONNET account, you can begin accessing hundreds of cancer immunotherapy resources in the SITC CONNECT Archive and Resource Libraries. Once your account is created, return to this page, refresh, and a download link should appear.
The SITC connectED education portal is supported by independent educational grants from AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com